


PRESS RELEASE



NUCLEA
BIOTECHNOLOGIES

For Further Information Contact:

Patrick J. Muraca, President and CEO
Nuclea Biotechnologies, LLC
105 South Street Pittsfield, MA 01201
413-749-7405 (Ph) 413-445-9930 (Fax)

Nuclea Biotechnologies, LLC
Clark University Lasery Center for
Bioscience Sackler Sciences Center
950 Main Street Worcester, MA 01601
Email: pr@nucleabio.com
www.nucleabiotech.com

PRESS RELEASE

FOR IMMEDIATE RELEASE

**NUCLEA BIOTECHNOLOGIES, LLC ANNOUNCES TODAY THE CLOSING OF A
\$3.4 MILLION DOLLAR PRIVATE PLACEMENT**

Worcester and Pittsfield, MA.....November 5th , 2009.....Nuclea Biotechnologies, LLC
Announced today the closing of a \$3.4 Million Dollar Private Placement. This offering is for Preferred Units of the Company. The Company had a Private Placement closing upon receiving commitments for \$3.4 million dollars of Preferred Units, prior to deducting placement agent fees, legal fees and other offering expenses payable by the Company.

The Nuclea's business strategy is as follows: Near-term, it is anticipated that growth will come from increasing sales of the Company's existing and new diagnostic assays, and increased service contracts between the Company and major pharmaceutical companies. In the mid-term, revenue growth should be enhanced by out-licensing and commercial collaborations with pharmaceutical companies of therapeutics developed by Nuclea's therapeutics subsidiary, Nuclea Biotherapeutics, LLC. In the long-term, Nuclea expects significant growth from the development and sale of pharmaceutical products arising out of the commercialization of Nuclea's patent protected intellectual property portfolio.

Nuclea Biotechnologies, LLC
www.nucleabiotech.com
Phone: 413-749-4705 Fax: 413-445-99302

The proceeds will be used to finance the commercialization of the Company's diagnostic tests and the development of additional diagnostic tests, maintain and expand the Company's collaborations with the Dana Farber Cancer Institute and the Johns Hopkins School of Medicine; and provide working capital for general business purposes.

"We are very pleased with this Private Placement closing of \$3.4 million dollars" states Patrick Muraca, President and CEO. "This infusion of capital allows the continuation of our strategy to commercialize new testing modalities in the personalized medicine space.

Muraca also stated "the new capital will also allow us to continue the therapeutic development of our multiple tyrosine kinase inhibitor in very serious diseases such as breast and colon cancer."

Nuclea Biotechnologies, LLC is a Delaware limited liability company based in Pittsfield and Worcester, Massachusetts. Nuclea has three lines of business, each of which is operated by a separate wholly-owned subsidiary: Nuclea Diagnostic Laboratories ("NDL") which has developed and is commercializing five unique diagnostic tests for colon, breast, leukemia, lung and prostate cancer; Nuclea Biomarkers ("NBM") which performs research leading to novel molecular oncology therapeutics and diagnostics for the pharmaceutical and biotechnology industries and performs services by analyzing and testing the efficacy and validating other indications of existing therapeutics utilizing a highly characterized and consented patient database; and Nuclea Biotherapeutics ("NBT") which has developed several therapeutics now in animal trials.

Nuclea Biotechnologies, LLC

www.nucleabiotech.com

Phone: 413-749-4705 Fax: 413-445-9930

